GlassScriptPhysician profile
Lakesha E Jones
NPI 1649804469
$7,373.22
in general payments reported to CMS, 2019-2025
23 companies · $819 in 2025
The $819 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,444 · 2022: $1,926 · 2023: $1,454 · 2024: $1,730 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,038.94 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $906.21 | 2021-2025 | Caplyta |
| Abbvie INC. | $896.44 | 2021-2025 | |
| Alkermes, INC. | $829.93 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $810.64 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $734.98 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Novo Nordisk INC | $366.99 | 2022 | |
| Vanda Pharmaceuticals INC. | $310.48 | 2023-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $237.79 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $185.88 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Si-Bone, INC. | $133.23 | 2022 | |
| Edwards Lifesciences Corporation | $125.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.81 | 2021-2022 | |
| Scynexis, INC. | $101.19 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hydrofera LLC | $91.41 | 2023 | Hydrofera Blue |
| Gilead Sciences, INC. | $85.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $69.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $57.22 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $56.97 | 2024 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $47.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.79 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $21.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakesha Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.